Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
NCT06561308Phase 2Recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in endometrial cancer (EC), sponsored by Women's Hospital, Zhejiang University School of Medicine. Started Sep 2025; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06561308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561308.